Cargando…

Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers

Categorization of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucioni, Marco, Berti, Emilio, Arcaini, Luca, Croci, Giorgio A., Maffi, Aldo, Klersy, Catherine, Goteri, Gaia, Tomasini, Carlo, Quaglino, Pietro, Riboni, Roberta, Arra, Mariarosa, Dallera, Elena, Grandi, Vieri, Alaibac, Mauro, Ramponi, Antonio, Rattotti, Sara, Cabras, Maria Giuseppina, Franceschetti, Silvia, Fraternali‐Orcioni, Giulio, Zerbinati, Nicola, Onida, Francesco, Ascani, Stefano, Fierro, Maria Teresa, Rupoli, Serena, Gambacorta, Marcello, Zinzani, Pier Luigi, Pimpinelli, Nicola, Santucci, Marco, Paulli, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083727/
https://www.ncbi.nlm.nih.gov/pubmed/27665744
http://dx.doi.org/10.1002/cam4.865
_version_ 1782463265667809280
author Lucioni, Marco
Berti, Emilio
Arcaini, Luca
Croci, Giorgio A.
Maffi, Aldo
Klersy, Catherine
Goteri, Gaia
Tomasini, Carlo
Quaglino, Pietro
Riboni, Roberta
Arra, Mariarosa
Dallera, Elena
Grandi, Vieri
Alaibac, Mauro
Ramponi, Antonio
Rattotti, Sara
Cabras, Maria Giuseppina
Franceschetti, Silvia
Fraternali‐Orcioni, Giulio
Zerbinati, Nicola
Onida, Francesco
Ascani, Stefano
Fierro, Maria Teresa
Rupoli, Serena
Gambacorta, Marcello
Zinzani, Pier Luigi
Pimpinelli, Nicola
Santucci, Marco
Paulli, Marco
author_facet Lucioni, Marco
Berti, Emilio
Arcaini, Luca
Croci, Giorgio A.
Maffi, Aldo
Klersy, Catherine
Goteri, Gaia
Tomasini, Carlo
Quaglino, Pietro
Riboni, Roberta
Arra, Mariarosa
Dallera, Elena
Grandi, Vieri
Alaibac, Mauro
Ramponi, Antonio
Rattotti, Sara
Cabras, Maria Giuseppina
Franceschetti, Silvia
Fraternali‐Orcioni, Giulio
Zerbinati, Nicola
Onida, Francesco
Ascani, Stefano
Fierro, Maria Teresa
Rupoli, Serena
Gambacorta, Marcello
Zinzani, Pier Luigi
Pimpinelli, Nicola
Santucci, Marco
Paulli, Marco
author_sort Lucioni, Marco
collection PubMed
description Categorization of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus‐based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Upon the histologic features that are listed in the WHO classification, 96 cases were classified as PCFCCL and 25 as PCDLBCL‐LT; 40 further cases did not fit in the former subgroups in terms of cytology and/or architecture, thus were classified as PCDLBCL, not otherwise specified (PCDLBCL‐NOS). We assigned all the cases a histogenetic profile, based on the immunohistochemical detection of CD10, BCL6, and MUM1, and a “double hit score” upon positivity for BCL2 and MYC. PCDLBCL‐NOS had a clinical presentation more similar to PCFCCL, whereas the histology was more consistent with the picture of a diffuse large B‐cell lymphoma, as predominantly composed of centroblasts but with intermixed a reactive infiltrate of small lymphocytes. Its behavior was intermediate between the other two forms, particularly when considering only cases with a “non‐germinal B‐cell” profile, whereas “germinal center” cases resembled PCFCCL. Our data confirmed the aggressive behavior of PCDLBC‐LT, which often coexpressed MYC and BCL2. The impact of single factors on 5‐year survival was documented, particularly histogenetic profile in PCDLBCL and BCL2 translocation in PCFCCL. Our study confirms that a further group—PCDLBCL‐NOS—exists, which can be recognized through a careful combination of histopathologic criteria coupled with adequate clinical information.
format Online
Article
Text
id pubmed-5083727
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50837272016-10-31 Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers Lucioni, Marco Berti, Emilio Arcaini, Luca Croci, Giorgio A. Maffi, Aldo Klersy, Catherine Goteri, Gaia Tomasini, Carlo Quaglino, Pietro Riboni, Roberta Arra, Mariarosa Dallera, Elena Grandi, Vieri Alaibac, Mauro Ramponi, Antonio Rattotti, Sara Cabras, Maria Giuseppina Franceschetti, Silvia Fraternali‐Orcioni, Giulio Zerbinati, Nicola Onida, Francesco Ascani, Stefano Fierro, Maria Teresa Rupoli, Serena Gambacorta, Marcello Zinzani, Pier Luigi Pimpinelli, Nicola Santucci, Marco Paulli, Marco Cancer Med Clinical Cancer Research Categorization of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus‐based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Upon the histologic features that are listed in the WHO classification, 96 cases were classified as PCFCCL and 25 as PCDLBCL‐LT; 40 further cases did not fit in the former subgroups in terms of cytology and/or architecture, thus were classified as PCDLBCL, not otherwise specified (PCDLBCL‐NOS). We assigned all the cases a histogenetic profile, based on the immunohistochemical detection of CD10, BCL6, and MUM1, and a “double hit score” upon positivity for BCL2 and MYC. PCDLBCL‐NOS had a clinical presentation more similar to PCFCCL, whereas the histology was more consistent with the picture of a diffuse large B‐cell lymphoma, as predominantly composed of centroblasts but with intermixed a reactive infiltrate of small lymphocytes. Its behavior was intermediate between the other two forms, particularly when considering only cases with a “non‐germinal B‐cell” profile, whereas “germinal center” cases resembled PCFCCL. Our data confirmed the aggressive behavior of PCDLBC‐LT, which often coexpressed MYC and BCL2. The impact of single factors on 5‐year survival was documented, particularly histogenetic profile in PCDLBCL and BCL2 translocation in PCFCCL. Our study confirms that a further group—PCDLBCL‐NOS—exists, which can be recognized through a careful combination of histopathologic criteria coupled with adequate clinical information. John Wiley and Sons Inc. 2016-09-26 /pmc/articles/PMC5083727/ /pubmed/27665744 http://dx.doi.org/10.1002/cam4.865 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Lucioni, Marco
Berti, Emilio
Arcaini, Luca
Croci, Giorgio A.
Maffi, Aldo
Klersy, Catherine
Goteri, Gaia
Tomasini, Carlo
Quaglino, Pietro
Riboni, Roberta
Arra, Mariarosa
Dallera, Elena
Grandi, Vieri
Alaibac, Mauro
Ramponi, Antonio
Rattotti, Sara
Cabras, Maria Giuseppina
Franceschetti, Silvia
Fraternali‐Orcioni, Giulio
Zerbinati, Nicola
Onida, Francesco
Ascani, Stefano
Fierro, Maria Teresa
Rupoli, Serena
Gambacorta, Marcello
Zinzani, Pier Luigi
Pimpinelli, Nicola
Santucci, Marco
Paulli, Marco
Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title_full Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title_fullStr Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title_full_unstemmed Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title_short Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers
title_sort primary cutaneous b‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: comparison with current classification and definition of prognostic markers
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083727/
https://www.ncbi.nlm.nih.gov/pubmed/27665744
http://dx.doi.org/10.1002/cam4.865
work_keys_str_mv AT lucionimarco primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT bertiemilio primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT arcainiluca primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT crocigiorgioa primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT maffialdo primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT klersycatherine primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT goterigaia primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT tomasinicarlo primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT quaglinopietro primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT riboniroberta primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT arramariarosa primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT dalleraelena primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT grandivieri primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT alaibacmauro primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT ramponiantonio primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT rattottisara primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT cabrasmariagiuseppina primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT franceschettisilvia primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT fraternaliorcionigiulio primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT zerbinatinicola primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT onidafrancesco primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT ascanistefano primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT fierromariateresa primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT rupoliserena primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT gambacortamarcello primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT zinzanipierluigi primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT pimpinellinicola primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT santuccimarco primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers
AT paullimarco primarycutaneousbcelllymphomaotherthanmarginalzoneclinicopathologicanalysisof161casescomparisonwithcurrentclassificationanddefinitionofprognosticmarkers